In my last blog, I wrote that psychedelics were the next frontier in substance use disorder (SUD) treatment. Certainly as we look at the current landscape and how it is poised to affect the future, the notion has merit. But there’s another drug category – Glucagon-like peptide-1s, or GLP-1s – that we could include in that category.
CMS and PA DHS have shared guidance on medical frailty and retroactive coverage with the upcoming H.R. 1 Medicaid changes.
As part of National Disability Employment Awareness Month (NDEAM), the PA ABLE Savings Program is hosting a free webinar series in October.